AstraZeneca Wins U.S. Ruling to Block Generic Crestor

AstraZeneca Plc, the U.K.’s second-biggest drugmaker, won an appeals court ruling that will block generic versions of its top-selling cholesterol medicine Crestor in the U.S. until July 2016.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.